, Estonia
€7,800,000
February 17, 2026 at 11:00
Supplies
304907
For detailed contact information, please refer to the official procurement documents.
Sign up to view complete requirements and analysis
No credit card required • Setup in 2 minutes
Sign up to view document summaries and analysis
No credit card required • Setup in 2 minutes
This tender for antineoplastic drugs is generally well-structured and transparent, particularly regarding its clear evaluation criteria and fair access. However, the absence of a specified contract duration and start date for the framework agreement represents a notable gap in completeness and practicality.
The tender demonstrates good legal compliance with reasonable submission deadlines, a clearly defined CPV code, and no reported disputes. The procedure type is clarified as an open procedure within the documents, despite generic codes in the basic information.
The tender's description, requirements, and evaluation criteria are exceptionally clear. Document 1 explicitly states that evaluation is based solely on the lowest cost per drug part, directly addressing the automated flag regarding missing criteria.
While most essential information is provided, a significant omission is the explicit duration and start date of the framework agreement. The NUTS code is also missing, though the organization's location is clear.
This tender scores highly on fairness due to full document access, disclosed estimated value, reasonable preparation time, objective 'lowest price' evaluation criteria, and enabled e-procurement. Requirements appear generic and not tailored to a specific company, with the tender divided into 25 parts to encourage broader participation.
Electronic submission is supported, which is practical. However, the absence of a clear contract start date and duration for the framework agreement poses a practical challenge for bidders in planning and commitment.
Key fields are mostly populated, and dates are logical. There are no reported suspensions or disputes. The only minor inconsistency is the automated flag regarding evaluation criteria, which is contradicted by the tender documents themselves.
The tender does not include any explicit green procurement, social, or innovation criteria, nor is it indicated as EU-funded. This is common for pharmaceutical tenders but results in a lower score for this category.
Sign up to view complete requirements and analysis
No credit card required • Setup in 2 minutes
Ask me anything about this tender
Hello! I'm your AI assistant for this tender. I can help you understand requirements, deadlines, eligibility criteria, and provide strategic insights.
No credit card required
Setup in 2 minutes